9 results on '"Bell, Allison M."'
Search Results
2. Managing acute bacterial skin and skin structure infections: Focus on new lipoglycopeptides.
- Author
-
Bell, Allison M., King, S. Travis, Barber, Katie E., Adcock, Kim G., Wagner, Jamie L., and Stover, Kayla R.
- Subjects
- *
ANTI-infective agents , *BACTERIAL disease prevention , *VANCOMYCIN , *PEPTIDE antibiotics , *COMMUNICABLE disease epidemiology , *ANTIBIOTICS , *COMMUNICABLE diseases , *DRUG resistance in microorganisms , *DRUG toxicity , *HOSPITAL care , *GRAM-positive bacterial infections , *SKIN diseases , *DRUG approval , *METHICILLIN-resistant staphylococcus aureus , *SOFT tissue infections , *THERAPEUTICS , *DISEASE risk factors - Abstract
Acute bacterial skin and skin structure infections (ABSSSI) are some of the most commonly encountered infections worldwide. Hospitalizations as a result of ABSSSI are associated with high mortality. This article discusses the role of oritavancin and dalbavancin, two new lipoglycopeptides, in the context of the other I.V. available standard therapy options. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
3. Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C.
- Author
-
Bell, Allison M., Wagner, Jamie L., Barber, Katie E., and Stover, Kayla R.
- Subjects
- *
HEPATITIS C vaccines , *QUINOXALINES , *DISEASE prevalence , *PROTEASE inhibitors , *CIRRHOSIS of the liver , *GENOTYPES , *DRUG side effects - Abstract
Hepatitis C virus (HCV) is estimated to affect up to 150 million people worldwide. Despite worldwide prevalence, treatment modalities prior to 2011 remained suboptimal, with low virologic response rates and intolerable side effect profiles. Fortunately, the landscape of treatment for chronic hepatitis C has rapidly evolved since the introduction of HCV NS3/4 protease inhibitors in 2011. Elbasvir, a NS5A inhibitor, combined with grazoprevir, a NS3/4A protease inhibitor, is the latest FDA-approved therapy for patients with genotype 1 or 4 chronic hepatitis C, with or without compensated cirrhosis. This review will focus on the current literature and clinical evidence supporting elbasvir/grazoprevir as first-line therapy in patients with genotypes 1 and 4 chronic hepatitis C. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
4. A clinical pathway for community-acquired pneumonia: an observational cohort st.
- Author
-
Frei, Christopher R., Bell, Allison M., Traugott, Kristi A., Jaso, Terry C., Daniels, Kelly R., Mortensen, Eric M., Restrepo, Marcos I., Oramasionwu, Christine U., Ruiz, Andres D., Mylchreest, William R., Sikirica, Vanja, Raut, Monika R., Fisher, Alan, and Schein, Jeff R.
- Subjects
- *
COMMUNITY-acquired pneumonia , *ANTIBIOTICS , *MEDICAL care costs , *HOSPITAL admission & discharge , *AZITHROMYCIN - Abstract
Background: Six hospitals instituted a voluntary, system-wide, pathway for community acquired pneumonia (CAP). We proposed this study to determine the impact of pathway antibiotics on patient survival, hospital length of stay (LOS), and total hospital cost. Methods: Data were collected for adults from six U.S. hospitals with a principal CAP discharge diagnosis code, a chest infiltrate, and medical notes indicative of CAP from 2005-2007. Pathway and non-pathway cohorts were assigned according to antibiotics received within 48 hours of admission. Pathway antibiotics included levofloxacin 750 mg monotherapy or ceftriaxone 1000 mg plus azithromycin 500 mg daily. Multivariable regression models assessed 90-day mortality, hospital LOS, total hospital cost, and total pharmacy cost. Results: Overall, 792 patients met study criteria. Of these, 505 (64%) received pathway antibiotics and 287 (36%) received non-pathway antibiotics. Adjusted means and p-values were derived from Least Squares regression models that included Pneumonia Severity Index risk class, patient age, heart failure, chronic obstructive pulmonary disease, and admitting hospital as covariates. After adjustment, patients who received pathway antibiotics experienced lower adjusted 90-day mortality (p = 0.02), shorter mean hospital LOS (3.9 vs. 5.0 days, p < 0.01), lower mean hospital costs ($2,485 vs. $3,281, p = 0.02), and similar mean pharmacy costs ($356 vs. $442, p = 0.11). Conclusions: Pathway antibiotics were associated with improved patient survival, hospital LOS, and total hospital cost for patients admitted to the hospital with CAP. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
5. Acute hepatic injury with amphotericin B deoxycholate in an immunocompetent patient.
- Author
-
Wagner, Jamie L. and Bell, Allison M.
- Subjects
- *
LIVER failure , *AMPHOTERICIN B , *ANTIFUNGAL agents , *FUNGEMIA , *DEOXYCHOLIC acid , *NEPHROTOXICOLOGY , *NUTRITIONAL status , *DRUG side effects - Abstract
Amphotericin B deoxycholate (AmBd) is rarely used due to its adverse effect profile, which includes nephrotoxicity, infusion-related reactions, and hepatotoxicity. The incidence of hepatotoxicity related to AmBd is 18-23%, but the reports of this adverse effect are mainly in immunocompromised patients receiving chemotherapy. We report a case of AmBd-related acute hepatic injury in an immunocompetent male with multiple medical problems. The patient initially had acute hepatic injury likely caused by poor nutritional status and a diagnosis of failure to thrive, but was recovering. He was also diagnosed with bilateral renal fungal mycetomas and received systemic treatment initially with micafungin and then fluconazole after urine cultures returned with the growth of Candida glabrata. Therapy was expanded to systemic AmBd when the fungal balls persisted. The patient subsequently developed hepatic re-injury with 1 dose of AmBd, and the therapy was discontinued. Caution should be exerted when utilizing AmBd in treating patients with previous hepatic injury. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
6. Ceftriaxone as an Alternative Therapy for the Treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia after Initial Clearance of Bloodstream Infection.
- Author
-
Barber, Katie E., Cramer, Rachel A., Bell, Allison M., Wagner, Jamie L., and Stover, Kayla R
- Subjects
- *
CEFTRIAXONE , *LEUKOCYTE count , *STAPHYLOCOCCUS aureus , *BACTEREMIA , *NOSOCOMIAL infections - Abstract
Introduction. Staphylococcus spp. represent the leading cause of hospital-acquired infections and second-most frequent pathogen in bloodstream infections. Methicillin-susceptible S. aureus (MSSA) comprise approximately half of all S. aureus isolates. Standard-of-care therapies (SOCTs) display high treatment success but require frequent dosing, are problematic in penicillin allergic patients, and are nephrotoxic. Ceftriaxone may represent an alternative treatment option. Methods. Adult patients hospitalized from January 2015 through June 2016 with positive MSSA blood cultures and treated with SOCT or ceftriaxone for ≥48 hours were included. Exclusion criteria were receipt of vancomycin or concomitant systemic antimicrobials with activity against MSSA, polymicrobial infections, and pregnant patients. Additional data collected included demographics, source/site of infection, and treatment. The primary endpoint was clinical cure (normalization of white blood cell count and temperature within 7 days and clearance of bloodstream within 7 days). Readmission within 60 days, length of stay, and discharge disposition were collected. Results. A total of 43 patients were included: 23 receiving SOCT and 20 receiving ceftriaxone group. Sixteen patients received SOCT prior to ceftriaxone while 4 patients were initiated on ceftriaxone. Clinical cure was observed in 18/23 (78%) and 10/20 (50%), respectively (P = 0.052). Clinical failure was driven by leukocytosis despite clearance of their bloodstream infection in 3/23 (13%) SOCT group compared to 8/20 (40%) in the ceftriaxone group (P = 0.043). Six patients (SOCT: 2, ceftriaxone: 4; p = 0.669) had infection-related readmissions, and 1 death per group was observed. Conclusion. Ceftriaxone poses a reasonable alternative to consider for MSSA bacteremia when cost and feasibility are concerns for outpatient parenteral therapy after initial clearance of bloodstream infections. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
7. Felons Need Not Apply: The Tough-on-crime Era's Felony Welfare Benefits Ban and its Impact on Families with a Formerly Incarcerated Parent.
- Author
-
Morgan, Amy A., Kosi-Huber, Jacob, Farley, Tatjana M., Tadros, Eman, and Bell, Allison M.
- Subjects
- *
LABOR laws , *PUBLIC welfare laws , *RACISM , *PRISONERS , *FAMILY support , *GOVERNMENT regulation , *CRIMINALS , *CULTURAL pluralism , *SOCIAL security , *CONCEPTUAL structures , *GOVERNMENT policy , *POLICY sciences , *PARENTS , *SOCIAL responsibility - Abstract
Although incarceration rates have begun to decline, the collateral consequences of mass incarceration persist, especially for families and communities of color. Following incarceration, families often face relationship, social, and financial challenges. Yet, social welfare benefits that can support families experiencing poverty frequently exclude people with felony convictions. One such social welfare policy—the focus of this paper—is the Personal Responsibility and Work Opportunity Reconciliation Act (PRWORA), which bars people with felony drug convictions from accessing social welfare benefits. With 60% of incarcerated parents having felony drug convictions, this policy precludes almost 200,000 families from accessing welfare benefits and disproportionately impacts single mothers and people of color. In this paper, we analyze PRWORA as it relates to social welfare and family inequity in the era of mass incarceration. Guided by an intersectionality framework, we address the following aims: (1) demonstrate how PRWORA may act as a form of institutional racism embedded within mass incarceration; and (2) analyze the impact of PRWORA's felony welfare benefits ban on families impacted by incarceration. We conclude with recommendations for researchers, policymakers, and practitioners working toward better outcomes for the formerly incarcerated. Highlights: Mass incarceration is a discriminatory institution of oppression that disproportionately impacts people with historically marginalized identities. Families with an incarcerated parent frequently experience secondary punishment through social stigma and economic strain. Social welfare may economically support families impacted by incarceration, yet many are disallowed welfare benefits under PRWORA. Excluding justice involved families from welfare benefits is a form of social exclusion embedded within mass incarceration. Until PRWORA's felony welfare benefits ban is repealed, justice involved families will likely be further marginalized. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. A clinical pathway for community-acquired pneumonia: an observational cohort study.
- Author
-
Frei, Christopher R, Bell, Allison M, Traugott, Kristi A, Jaso, Terry C, Daniels, Kelly R, Mortensen, Eric M, Restrepo, Marcos I, Oramasionwu, Christine U, Ruiz, Andres D, Mylchreest, William R, Sikirica, Vanja, Raut, Monika R, Fisher, Alan, and Schein, Jeff R
- Abstract
Background: Six hospitals instituted a voluntary, system-wide, pathway for community acquired pneumonia (CAP). We proposed this study to determine the impact of pathway antibiotics on patient survival, hospital length of stay (LOS), and total hospital cost.Methods: Data were collected for adults from six U.S. hospitals with a principal CAP discharge diagnosis code, a chest infiltrate, and medical notes indicative of CAP from 2005-2007. Pathway and non-pathway cohorts were assigned according to antibiotics received within 48 hours of admission. Pathway antibiotics included levofloxacin 750 mg monotherapy or ceftriaxone 1000 mg plus azithromycin 500 mg daily. Multivariable regression models assessed 90-day mortality, hospital LOS, total hospital cost, and total pharmacy cost.Results: Overall, 792 patients met study criteria. Of these, 505 (64%) received pathway antibiotics and 287 (36%) received non-pathway antibiotics. Adjusted means and p-values were derived from Least Squares regression models that included Pneumonia Severity Index risk class, patient age, heart failure, chronic obstructive pulmonary disease, and admitting hospital as covariates. After adjustment, patients who received pathway antibiotics experienced lower adjusted 90-day mortality (p = 0.02), shorter mean hospital LOS (3.9 vs. 5.0 days, p < 0.01), lower mean hospital costs ($2,485 vs. $3,281, p = 0.02), and similar mean pharmacy costs ($356 vs. $442, p = 0.11).Conclusions: Pathway antibiotics were associated with improved patient survival, hospital LOS, and total hospital cost for patients admitted to the hospital with CAP. [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF
9. Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease in Adults.
- Author
-
Malinowski, Scott S., Byrd, Jennifer S., Bell, Allison M., Wofford, Marion R., and Riche, Daniel M.
- Subjects
- *
FATTY liver , *THERAPEUTICS , *TRIGLYCERIDES , *LIVER cells , *CIRRHOSIS of the liver , *LIVER cancer , *PHARMACOLOGY - Abstract
Nonalcoholic fatty liver disease ( NAFLD) is characterized by the accumulation of triglycerides in hepatocytes in the absence of excessive alcohol intake, ranging in severity from simple steatosis to nonalcoholic steatohepatitis ( NASH). Nonalcoholic steatohepatitis can ultimately progress to cirrhosis and hepatocellular carcinoma. NAFLD is associated with cardiometabolic risk factors and is the most common chronic liver disease among adults in the Western Hemisphere. Although simple steatosis is generally considered a self-limiting disease, evidence suggests an increased risk of cardiovascular disease, and, less conclusively, mortality, among individuals with NAFLD and/or NASH. The current standard of care for the treatment of patients with NAFLD focuses on lifestyle interventions, particularly diet and exercise. There is a lack of consensus regarding the most effective and appropriate pharmacologic therapy. A Pub Med search was conducted using the medical subject heading terms 'fatty liver' and 'steatohepatitis.' This review focuses on the current pharmacologic options available for treating adults with NAFLD and/or NASH. Continued investigation of drugs or combinations that improve NAFLD progression is crucial. Clinicians, particularly pharmacists, must take an active role in identification and appropriate selection of pharmacotherapy for NAFLD. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.